Enfuvirtide
HIV fusion inhibitor.
What it is
Enfuvirtide (Fuzeon) is a synthetic 36-amino-acid peptide that functions as an HIV fusion inhibitor. It was FDA-approved in 2003 for HIV infection in patients with multidrug-resistant virus.
Mechanism of action
Binds the gp41 envelope glycoprotein of HIV-1, preventing the conformational change required for viral fusion with the host cell membrane. The mechanism is distinct from other antiretroviral classes, providing utility against virus resistant to standard regimens.
Approved indications
HIV infection in patients with evidence of multidrug-resistant HIV-1 replication.
Why this is out of scope at The Tide
HIV care is appropriately managed by infectious disease specialists with experience in antiretroviral therapy. Enfuvirtide is used in specific scenarios involving multidrug-resistant HIV that require expert management. The Tide does not provide HIV care.
Where to learn more
Infectious disease providers specialized in HIV care.